Document is current
Any future updates will be listed below
-
Authors
Kasikova, Lenka
Rakova, Jana
Hensler, Michal
Lanickova, Tereza
Tomankova, Jana
Pasulka, Josef https://orcid.org/0000-0001-6190-0465
Drozenova, Jana
Mojzisova, Katerina
Fialova, Anna https://orcid.org/0000-0003-1436-5142
Vosahlikova, Sarka
Laco, Jan
Ryska, Ales
Dundr, Pavel
Kocian, Roman
Brtnicky, Tomas https://orcid.org/0000-0002-6204-1903
Skapa, Petr
Capkova, Linda
Kovar, Marek https://orcid.org/0000-0002-6602-1678
Prochazka, Jan https://orcid.org/0000-0003-4675-8995
Praznovec, Ivan
Koblizek, Vladimir
Taskova, Alice
Tanaka, Hisashi https://orcid.org/0000-0001-9223-4186
Lischke, Robert
Mendez, Fernando Casas
Vachtenheim, Jiri Jr https://orcid.org/0000-0002-1468-4242
Heinzelmann-Schwarz, Viola
Jacob, Francis https://orcid.org/0000-0002-0446-1942
McNeish, Iain A. https://orcid.org/0000-0002-9387-7586
Halaska, Michal J.
Rob, Lukas
Cibula, David
Orsulic, Sandra https://orcid.org/0000-0001-5119-8721
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
Spisek, Radek
Fucikova, Jitka https://orcid.org/0000-0002-8423-479X
- License Information
-
More Information
Article History
Received: 29 September 2022
Accepted: 13 March 2024
First Online: 21 March 2024
Competing interests
: L.G. is/has been holding research contracts with Lytix Biopharma, Onxeo and Promontory, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Sotio, Promontory, Noxopharm and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. R.Sp. is minority shareholder of Sotio Biotech a.s. A.R. declare advisory services and invited lectures for Amgen, AstraZeneca, BMS, Eli-Lilly, Janssen-Cilag, MSD, Roche. All other authors have no conflicts to declare.
